YHB Investment Advisors Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 151,760 shares of the biopharmaceutical company’s stock after purchasing an additional 16,352 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Pfizer were worth $5,497,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after acquiring an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after acquiring an additional 1,085,437 shares in the last quarter. 71.41% of the stock is currently owned by institutional investors.
PFE has been the topic of several recent analyst reports. Morningstar set a $38.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $39.40.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 EPS. equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were issued a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.74%. Pfizer’s dividend payout ratio is presently 38.75%.
Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares in the company, valued at approximately $1,374,505.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mikael Dolsten sold 69,699 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the sale, the insider now owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 262,787 shares of company stock valued at $9,611,095. 0.06% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/03/15/yhb-investment-advisors-inc-acquires-16352-shares-of-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.